Cerebral Venous Thrombosis

1. THE 2-MINUTE PHYSIOLOGY (Rapid Pathophysiology)

• Definition and Classification: Cerebral venous thrombosis (CVT) encompasses dural sinus thrombosis (occlusion of the large dural venous conduits), cortical vein thrombosis (occlusion of the superficial cortical surface veins), or both.
• The Hemodynamic Breakdown: Pathophysiology is driven by Virchow's triad (venous stasis, hypercoagulability, and vessel wall injury). Once a thrombus forms, venous drainage from the cerebral parenchyma is obstructed, causing retrograde venous hypertension and capillary congestion. This leads to a breakdown of the blood-brain barrier, triggering vasogenic edema. If localized pressure continues to rise, capillary perfusion pressure drops, resulting in decreased cerebral blood flow, cytotoxic edema, cellular ischemia, and venous infarction.
• Hemorrhagic Transformation: Because venous walls are thin and lack muscular layers, capillary hypertension frequently leads to rupture and local hemorrhage, with approximately 30% to 40% of CVT patients presenting with a concomitant intracranial hemorrhage.
• Intracranial Hypertension and Herniation: Large thrombi can physically obstruct the arachnoid granulations, blocking normal cerebrospinal fluid (CSF) absorption. This dual mechanism of localized parenchymal edema and CSF outflow obstruction leads to progressive hydrocephalus, severe intracranial hypertension, and ultimately life-threatening transtentorial herniation (the leading cause of death in the acute phase).

2. THE BEDSIDE ACTION PLAN (Rapid ER Management)

• Airway and Breathing Stabilization: Assess airway patency and protection immediately. If the patient is obtunded, unable to manage oral secretions, or exhibits severe respiratory depression secondary to increased intracranial pressure (ICP), perform rapid sequence intubation (RSI). Avoid sudden spikes in systolic blood pressure (SBP) or mean arterial pressure (MAP) during intubation to prevent worsening any concomitant intracranial hemorrhage.
• Midline Head Positioning: Keep the patient’s head in a neutral midline position and elevated to 30° to optimize venous drainage and assist in reducing ICP.
• First-Line Anticoagulation (The Cornerstone of Therapy): Systemic anticoagulation must be initiated immediately upon diagnostic confirmation, even in the presence of an active concomitant intracranial hemorrhage. Anticoagulation prevents clot propagation, facilitates venous recanalization, and reduces the risk of systemic thromboembolism.
• Low-Molecular-Weight Heparin (LMWH) (Preferred): Administer Enoxaparin 1 mg/kg subcutaneous (SC) every 12 hours or 1.5 mg/kg SC every 24 hours. LMWH is preferred over unfractionated heparin (UFH) due to better outcomes and lower rates of hemorrhagic complications.
• Unfractionated Heparin (UFH) (Alternative): Use UFH if there is a direct contraindication to LMWH, severe renal impairment (Creatinine Clearance <30 mL/min), or an impending need for emergency neurosurgical intervention. Administer an 80 U/kg IV bolus, followed by a continuous infusion of 18 U/kg/hour, titrated to local institutional heparin nomograms.
• ICP-Lowering Rescue Measures (For Impending Herniation):
• Hyperosmolar Therapy: Administer Mannitol 1 to 1.5 g/kg IV of a 20% solution as a rapid bolus, or 3% Hypertonic Sodium Chloride 250 to 500 mL IV over 30 minutes. For acute, refractory herniation, 23.4% Sodium Chloride 30 mL IV can be administered over 15 to 20 minutes (ideally via central line, but peripherally in an emergent crush scenario) or weight-based at 0.43 mL/kg IV.
• Analgesia and Sedation: Control pain with Fentanyl 25 to 100 mcg IV loading dose (or 1 to 2 mcg/kg) followed by 50 to 200 mcg/hour continuous infusion to avoid pain-induced ICP spikes. Sedate with Midazolam (0.01 to 0.05 mg/kg IV loading, then 0.02 to 0.1 mg/kg/hour infusion) or Propofol (10 to 30 mcg/kg/min IV, titrated up to 50 to 80 mcg/kg/min).
• Seizure Management: Treat active seizures promptly with IV benzodiazepines (e.g., Lorazepam 2 to 8 mg IV or Midazolam 10 mg IV/IM) followed by non-sedating antiepileptics (e.g., Levetiracetam). Do not utilize prophylactic antiepileptic drugs in patients who have not had a seizure.

3. THE DIAGNOSTIC GRID (Differential Diagnosis & Workup)

• Top 5 "Can't-Miss" Mimics:

    1.  **Aneurysmal Subarachnoid Hemorrhage (aSAH):** Presents with an acute "thunderclap" headache, but can be distinguished by sudden onset peaking within seconds, prominent meningismus, and blood in the subarachnoid space on non-contrast CT.
    2.  **Acute Ischemic Stroke (Arterial Distribution):** Presents with focal neurological deficits, but follows a strict single-artery anatomical distribution, whereas CVT-associated infarctions typically cross vascular boundaries and frequently involve bilateral or atypical patterns.
    3.  **Idiopathic Intracranial Hypertension (Pseudotumor Cerebri):** Presents with headaches, papilledema, and elevated CSF opening pressures in young, obese females, but lacks dural sinus thrombus on MR venography.
    4.  **Meningitis or Encephalitis:** Presents with headache, altered mental status, and seizures, but is characterized by high fevers, prominent meningismus, and CSF inflammatory markers (pleocytosis).
    5.  **Reversible Cerebral Vasoconstriction Syndrome (RCVS):** Presents with recurrent thunderclap headaches, but shows characteristic segmental "string-of-beads" narrowing of cerebral arteries on angiography rather than venous sinus occlusion.

• Prioritized Diagnostic Workup Strategy:
• Urgent Neurovascular Imaging (CTV or MRV): Mandated immediately for suspected cases. Non-contrast head CT should be performed first but is inadequate to rule out CVT as it is normal in a majority of early cases.
• Basic Metabolic and Coagulation Panels: Obtain CBC (to rule out severe anemia or thrombocytopenia), CMP (to check electrolytes and renal function for medication dosing), and PT/INR/aPTT.
• Occult Hypercoagulability Screen: Send-out labs for inherited thrombophilias (Protein C/S deficiencies, Factor V Leiden, Antithrombin III) and acquired hypercoagulable states (lupus anticoagulant, antiphospholipid antibodies).
• Pregnancy Testing: Perform a urine or serum pregnancy test in all females of childbearing age, as pregnancy and the postpartum period are massive risk factors.
• The D-dimer Rule: D-dimer is not recommended in the routine workup of CVT. A normal D-dimer cannot reliably exclude CVT in high-risk patients, especially those with isolated headache, papilledema, or prolonged symptoms.

4. THE VISUAL BOARD (ECG / POCUS / Imaging)

• Standard ECG Checklist:
• Arrhythmia and Ischemia Screening: Screen for new-onset atrial fibrillation or QT prolongation. Up to 90% of patients with intracranial hemorrhage or elevated ICP can develop reactive arrhythmias or ST-T wave changes that can mimic primary cardiac ischemia.
• Point-of-Care Ultrasound (POCUS) Checklist:
• Optic Nerve Sheath Diameter (ONSD): Measure the ONSD bilaterally to screen for raised ICP. An ONSD >5.0 to 6.0 mm suggests intracranial hypertension.
• Head CT (Non-Contrast) Checklist:
• Direct Signs (Cord Sign): Look for a cord-like hyperdensity within a cortical vein or dural sinus (representing the acute clot), though this is seen in less than one-third of cases.
• Indirect Signs: Look for localized venous infarcts, lobar or bilateral parenchymal hemorrhages that cross traditional arterial boundaries, sulcal effacement, and gray-white matter dedifferentiation.
• CT Venography (CTV) or MR Venography (MRV) Checklist:
• The "Empty Delta Sign": On contrast-enhanced CTV, look for a triangular area of non-filling surrounded by contrast enhancement in the posterior superior sagittal sinus.
• Venous Flow Void Absence: On MRV, look for a lack of flow or signal void within the affected dural sinus or cortical vein to confirm occlusion.
• Note on Selection: MRI combined with MRV is the gold standard for diagnosing CVT and associated parenchymal lesions, but CTV is a highly reliable alternative if MRI is unavailable or contraindicated.

5. THE SCORING MATRIX (Risk Stratification & Guidelines)

• The Virchow Demographics Matrix: Clinical risk stratification relies heavily on identifying predisposing factors (present in >85% of cases). Risk factors include pregnancy, the puerperium (risk remains elevated for up to 6–8 weeks postpartum), oral contraceptive use (carrying a 20-fold increased risk of CVT, which increases to 30-fold in obese patients), and underlying malignancy.
• Factors Predictive of Poor Outcome: The presence of any of the following variables on admission predicts a significantly worse clinical prognosis and should lower the threshold for ICU admission:
• Age >37 years
• Male sex
• Altered mental status or Glasgow Coma Scale (GCS) score <9
• Concomitant intracranial hemorrhage on initial imaging
• Underlying malignancy
• Occlusion of a large venous sinus or posterior fossa lesions
• Admission hyperglycemia
• Systemic CNS infection (in contrast, infections outside the CNS do not correlate with worse outcomes)

6. THE DANGER ZONE (Pitfalls & Critical Actions)

• The "Hemorrhage Anticoagulation" Hesitation Trap: Withholding or delaying heparin because of the presence of a concomitant venous intracranial hemorrhage on CT. This is a deadly error; systemic anticoagulation is safe and recommended in CVT patients even with hemorrhage, as preventing clot propagation and restoring venous flow is the primary mechanism to halt bleeding.
• The "Normal Dry CT" Reassurance Fallacy: Excluding CVT because the initial non-contrast head CT is completely normal. A normal dry CT occurs in up to 70% of early CVT cases; if clinical suspicion is high (e.g., a pregnant patient with a progressive, persistent headache), contrast-enhanced CTV or MRV is mandatory.
• The Prophylactic Antiseizure Pitfall: Administering antiepileptic drugs prophylactically to CVT patients who have not had a seizure. Anticonvulsants should only be initiated once a clinical seizure has occurred.
• The D-dimer False Reassurance Trap: Relying on a normal D-dimer to rule out CVT in at-risk patients. D-dimer has inconsistent sensitivity and is frequently normal in patients with isolated headaches or subacute presentations.
• The Corticosteroid Administration Pitfall: Prescribing corticosteroids (e.g., dexamethasone) to treat vasogenic edema in CVT. Corticosteroids are not beneficial in CVT and are associated with worse clinical outcomes; they should be strictly avoided unless treating a specific underlying inflammatory or autoimmune trigger.
• Mandatory Critical Actions:
• Review pregnancy status and medication history (specifically OCPs or estrogen-containing therapies) in all young patients presenting with atypical headaches or stroke-like symptoms.
• Initiate immediate therapeutic anticoagulation with LMWH or UFH once CVT is confirmed, regardless of the presence of intracranial blood.
• Avoid the use of steroids in the acute management of CVT.
• Ensure all diagnosed CVT patients are admitted to a stroke unit or intensive care unit (ICU) due to the high risk of rapid clinical decompensation.

7. MCQ MASTERCLASS (Written Exam Tips)

• The Pregnancy/OCP Demographic: Written questions often describe a young, obese female on OCPs, or a postpartum patient (up to 6 to 8 weeks after delivery), presenting with a progressive, persistent headache that worsens with coughing or Valsalva maneuvers.
• Atypical Stroke Presentation: Suspect CVT on an exam when a patient presents with focal stroke symptoms (e.g., hemiparesis) accompanied by new-onset seizures, or with symptoms that cross different, non-arterial vascular distributions.
• The Elderly Somnolence Trap: In patients over the age of 55, headache is less common. Instead, the elderly classically present with progressive somnolence or altered mental status without focal deficits, representing bilateral thalamic venous infarctions.
• The "Cord Sign" vs. "Empty Delta Sign":
• Cord Sign: Hyperdensity of a thrombosed cortical vein on a non-contrast head CT.
• Empty Delta Sign: A triangular non-filling defect in the superior sagittal sinus surrounded by contrast enhancement on contrast CTV.
• Distractor Differentiations on Exams:
• Distractor: Initiating aspirin for acute management.
• Correction: While aspirin is prescribed at discharge, it has no role in the acute emergency management of CVT.
• Distractor: Delaying anticoagulation to obtain a repeat CT in 6 hours for a small parenchymal hemorrhage.
• Correction: Immediate anticoagulation is indicated; delaying therapy leads to clot propagation and worse hemorrhagic extension.
• Distractor: Administering dexamethasone to treat vasogenic edema.
• Correction: Steroids are associated with poorer outcomes in CVT and must be avoided.

8. THE BOARDROOM SCRIPT (OSCE & Oral Board Tips)

• Triage and Initial Assessment: "On arrival of this young female with a history of oral contraceptive use presenting with severe atypical headache, vomiting, and a new-onset seizure, I am placing her in a monitored resuscitation bay. I will assess her airway, breathing, and circulation, secure IV access, and obtain an immediate point-of-care capillary glucose to rule out hypoglycemia."
• Physical and Neurological Exam: "I will perform a focused neurological examination, assessing her Glasgow Coma Scale (GCS) score, cranial nerves, visual fields, and motor strength. I will perform a detailed fundoscopic exam to screen for papilledema, evaluate for a sixth cranial nerve palsy, and check for signs of autonomic dysregulation."
• Diagnostic Workup Phrasing: "Because this patient has a seizure and an atypical headache in the setting of oral contraceptive use, I have a high clinical suspicion for cerebral venous thrombosis (CVT). I will order a non-contrast head CT as our initial imaging study. However, because a normal dry CT cannot rule out CVT, I will immediately order a contrast-enhanced CT venography (CTV) or a magnetic resonance venography (MRV) to visualize the cerebral venous system. I will also send a complete blood count, coagulation profile, metabolic panel, and an hCG pregnancy test. I will not rely on a D-dimer to rule out this diagnosis given her high-risk profile."
• Therapeutic Execution and Contraindications: "Once CVT is confirmed, I will immediately initiate therapeutic anticoagulation. Even in the presence of a concomitant venous intracranial hemorrhage on CT, I will administer weight-based low-molecular-weight heparin, specifically Enoxaparin 1 mg/kg SC, as it is associated with improved outcomes and lower bleeding risks compared to UFH. I will explicitly state to my team that corticosteroids are not beneficial and are associated with worse outcomes, so I will not administer steroids. If she has another seizure, I will administer Lorazepam 2 to 4 mg IV, but I will not use prophylactic antiepileptic medications."
• Managing Elevated ICP (If clinically indicated): "If the patient develops signs of impending transtentorial herniation—such as progressive pupillary dilation, decerebrate posturing, bradycardia, or hypertension—I will elevate the head of the bed to 30°, optimize ventilation to maintain normocapnia, and administer hyperosmolar therapy with Mannitol 1 to 1.5 g/kg IV of a 20% solution or hypertonic 3% saline. I will obtain an emergent neurosurgical consultation to evaluate for a decompressive hemicraniectomy or ventriculostomy."
• Disposition Decision: "Because this patient is at extremely high risk for acute decompensation, I will obtain urgent consultations with neurology and hematology. She cannot be discharged home; I will admit her to the Stroke Unit or the Neurological Intensive Care Unit (ICU) for close, continuous cardiorespiratory and neurological monitoring."